The Democratic Republic of the Congo is enduring its 17th and largest Ebola outbreak, with the Bundibugyo strain killing 5,376 people and infecting more than 10,444 across three countries. The fatality rate exceeds 50 percent. There are no approved vaccines or treatments for this strain. That single fact defines the crisis. The DRC accounts for nearly all deaths — 5,372 of 5,376 — confirming the country's health system as the epicentre of both the disease and the structural failure to contain it. The outbreak was declared in mid-May, and months later the death toll continues climbing. Uganda recorded 20 cases, almost all linked to travellers from the DRC, and was declared Ebola-free in August after swift quarantine measures. Kenya recorded its first-ever Ebola cases in October: nine infections, two deaths. Nigeria tested two suspected cases in its northeast region; both came back negative. Abuja had reported its first imported case in over a decade in October but has recorded no deaths. France logged a single case in July involving a health worker returning from the DRC. The cross-border transmission pattern is clear: the virus follows human movement, and containment depends entirely on the weakest health system in the chain. The absence of a Bundibugyo-specific vaccine is the structural chokepoint. The Ervebo vaccine, effective against the more common Zaire strain, has entered clinical trials in recent weeks, but it does not cover the strain currently killing people. This is not a failure of science alone — it reflects decades of underinvestment in vaccines for rare strains that predominantly affect Central African populations. Health workers on the ground face direct physical danger. Attackers killed a nurse and injured another health worker responding to Ebola cases in the DRC, underscoring that the response operates in conflict-affected territory where armed groups treat aid infrastructure as a target. The human cost extends beyond the virus itself. The 50-percent fatality rate and 10,444 confirmed infections mean roughly one in two known cases ends in death. Clinical trials for Ervebo adaptation are a start, but the timeline for a Bundibugyo-specific intervention remains undefined. The DRC's health system — underfunded, overstretched, operating in active conflict zones — bears the overwhelming burden. Regional neighbours managed containment through aggressive quarantine, but the source country has no comparable capacity. If the Bundibugyo strain mutates or finds a more efficient transmission pathway before a vaccine arrives, the current death toll becomes a prologue. The global health architecture's response to this outbreak will be measured not by press conferences but by whether it closes the vaccine gap before the next border crossing.
